Among the trade-offs that come with antipsychotic medication, weight gain is one of the most consequential. It contributes to diabetes, cardiovascular disease, distress, and treatment dropout. Almost every commonly used antipsychotic causes weight gain to some degree. Molindone, sold historically as Moban, is one of the few exceptions — and is sometimes the only exception that matters when the metabolic stakes are particularly high.
Molindone is an older first-generation antipsychotic notable for being weight-neutral or even causing weight loss — a profile that, despite limited US availability, keeps the drug clinically interesting.
What molindone is
Molindone is a dihydroindolone — a chemically distinctive class of its own — and was FDA-approved in 1974 for the management of schizophrenia. It blocks dopamine D2 receptors and has some serotonin and adrenergic activity. Clinically, it behaves like a first-generation antipsychotic with a side effect profile that is heavier on EPS than second-generation drugs but lighter on metabolic effects than nearly anything else.
The weight effect
The most distinctive thing about molindone is what it does (or doesn't do) to weight. Multiple studies, including the TEOSS trial in childhood-onset schizophrenia (published in the American Journal of Psychiatry in 2008 and indexed at PubMed Central), found that molindone produced significantly less weight gain than risperidone or olanzapine. Some patients actually lost weight on molindone — a result that is essentially unheard of among other first-line options.
The mechanism is not fully understood. Theories include weak histamine H1 affinity, weak 5-HT2C affinity, and perhaps direct effects on appetite-regulating circuits. Whatever the mechanism, the clinical observation has held up across decades.
The TEOSS finding
The Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study compared molindone, risperidone, and olanzapine in children and adolescents with schizophrenia spectrum disorders. The headline finding was that all three drugs produced similar improvements in psychotic symptoms, but olanzapine and risperidone caused substantial weight gain while molindone did not. The trial helped re-establish molindone in academic discussions, although its limited commercial availability has constrained its real-world impact.
Other side effects
EPS
Molindone causes a level of EPS comparable to other moderately potent first-generation drugs. Akathisia is common, parkinsonism is possible, and acute dystonia can occur in younger patients. See our EPS overview.
Akathisia
Restlessness — especially of the legs — is a frequent reason patients ask to switch off molindone. Strategies include dose reduction, propranolol, or low-dose benzodiazepines. See our akathisia guide.
Tardive dyskinesia
Long-term TD risk is comparable to other first-generation drugs and higher than with most second-generation agents. Annual AIMS exams are standard.
Sedation and anticholinergic effects
Sedation is generally mild to moderate. Anticholinergic effects are present but milder than with low-potency phenothiazines.
Hyperprolactinemia
Like other D2 blockers, molindone raises prolactin. See our hyperprolactinemia article.
Cardiovascular effects
Modest QTc effects; orthostatic hypotension is uncommon.
High fever, severe muscle rigidity, confusion, or autonomic instability appear together — possible NMS.
The availability problem
Molindone has had a difficult commercial history in the US. Brand-name Moban was discontinued in 2010, and generic supply has been intermittent ever since. Patients and prescribers who want to use molindone often have to navigate compounding pharmacies, periodic shortages, or simply switch to a different agent. As of recent years, generic molindone has been available again from selected manufacturers — but supply should be confirmed before starting it as a long-term plan.
Where molindone fits today
Despite the availability issues, molindone remains relevant as a teaching example and an occasional clinical option for:
- Patients with significant existing obesity or diabetes for whom further metabolic risk is not acceptable
- Patients who have gained intolerable weight on other antipsychotics
- Adolescents (per TEOSS-style reasoning) where long-term metabolic exposure is a particular concern
- Patients who responded to it historically
Who might not
- People with prior severe EPS or akathisia on first-generation drugs
- Older adults at higher TD risk
- People in regions where supply is unreliable
Practical questions to ask
- Is molindone reliably available in my pharmacy network right now?
- Given my metabolic history, how would the weight benefit weigh against the EPS risk?
- Are there second-generation alternatives with weaker weight effects (lurasidone, ziprasidone, aripiprazole, lumateperone) that might fit better with fewer movement side effects?
- How will we monitor for movement side effects over time?
The big picture
Molindone is a small but stubborn presence in the antipsychotic conversation. It exists because no other commonly used drug delivers what it delivers on the weight front — and as the metabolic toll of antipsychotic treatment becomes more widely recognised, that simple fact keeps it in mind. For some patients, especially those for whom further weight gain is not acceptable, it is worth knowing about and worth discussing with a prescriber. For others, the EPS profile and supply uncertainty make it a poor fit. The decision belongs to you and your clinician.
This article is for educational purposes only and is not medical advice. Information is summarised from publicly available FDA labelling and peer-reviewed literature. Always consult your prescribing clinician before starting, stopping, or changing any medication.